Kornimate/medical-research-clean huggingface dataset:
effect of twice daily application of coconut oil in reducing water loss from skin of premature babies in first week of life

Conditions: Trans Epidermal Water Loss

Summary: the skin of newborn infants is immature and ineffective as a barrier. preterm skin exhibits even more vulnerability to the environment due to poor self regulatory heat mechanisms, paucity of fatty tissue and its thinness. most preterm babies lose up to 13% of their weight as water loss from their skin during the first week of life. many strategies have been utilized by neonatologists to decrease this water loss. edible coconut oil application on the skin acts as a non permeable barrier and can help in achieving this. hence the investigators decided to undertake this study to objectively assess the reduction in water loss from skin after oil application.


Eligibility criteria:
inclusion criteria: all preterm babies born at the study center with birth weight \< 1500g were eligible for inclusion in the study. exclusion criteria: 1. babies with birth weight less than 750 gms at birth 2. babies with major congenital malformations. 3. babies with severe asphyxia, hydrops and shock. 4. babies with congenital diseases of skin associated with skin breach or denudation of skin precluding oil application 5. babies with preexisting skin infection such as multiple furuncles (2 or more skin areas - each limb, head, chest, abdomen and back are the individual areas that will be taken as one area)

Keywords: preterms coconut oil application trans epidermal water loss weight gain
growth hormone (gh) in congenital adrenal hyperplasia

Conditions: Adrenal Hyperplasia, Congenital

Summary: congenital adrenal hyperplasia (cah) is a genetic rare disease, which alters the adrenal production of gluco and mineralo corticoids. the treatment consists in supplementing children using hydrocortisone. despite care for these children has improve substantially across decades, short adult height still remains an important consequence of the disease. about 20 % of patients have an ah below 2 standard deviations compared to their expected height. in the opale model study, the investigators have collected data from a cohort of 496 french patients, born between 1970 and 1991 and with a known genotype. using their age, sex, growth, disease, bone maturation and pubertal data, they have built a model which allows to predict their ah using data available at 8 years of age. this model has shown that the currently used formula to calculate the predicted ah (bayley pineau's method) is not applicable to children with cah. in this project, the investigators plan to use the prediction model to compare the ah in patients who have received gh treatment to their predicted ah using the model. the hypothesis is that gh improves the ah in such patients. existing cohorts have shown improved growth celerity, and growth expectation using the bayley-pineau formula), but this has not been shown on the actual ah. this study will allow to reinforce the investigators' hypothesis.


Eligibility criteria:
inclusion criteria: patients with cah, born between 1970 and 1998, having received gh treatment for a minimal one year duration. exclusion criteria: * patients with chronic any growth altering disease, turner syndrome or other genetic anomaly; 8-year wrist xray and adult height should be available to allow the use of the opale model prediction.

Keywords: congenital adrenal hyperplasia short stature growth hormone treatment
observation vs early removal of lams in eus guided cholecystoenterostomy

Conditions: Cholecystitis, Acute; Cholecystitis; Gallstone

Summary: the study will compare the outcomes of patients with gallstone related cholecystitis who are poor surgical candidates undergoing eus guided cholecystoenterostomy via a lumen apposing metal stent (lams).

the study will include patients with stone related cholecystitis that are not adequate surgical candidates that will be treated with eus guided cholecystoenterostomy with endoscopic stone extraction. patients will be randomized to stent removal immediately after gallstones have been removed or to observation for 1 year with the stent in place. outcomes to be measured include recurrence of stone disease and rate of complications from the procedure in both groups

Eligibility criteria:
inclusion criteria: 1. ages 18-100 years or age 2. both genders 3. diagnosis of acute cholecystitis by tg13 criteria. 4. patients who are able to give consent 5. patients who are deemed poor surgical candidates for cholecystectomy by the surgical/medical team. exclusion criteria: 1. unable to provide informed consent 2. cardiorespiratory dysfunction that precludes sedation 3. pregnant females 4. presence of ascites (distance between duodenum and gb \> 1 cm) and/or coagulopathy (inr \> 3, plt \<20k)
vorinostat (mk-0683) phase i study in cutaneous t-cell lymphoma (ctcl) patients (mk-0683-089 ext1)

Conditions: Lymphoma

Summary: part i evaluates the safety, tolerability and pharmacokinetics (pk) of vorinostat in japanese patients with relapsed or refractory ctcl. part ii evaluates the safety of vorinostat in japanese pts. with relapsed or refractory ctcl. relapsed or refractory ctcl patients will be newly enrolled in part ii.


Eligibility criteria:
inclusion criteria (parts i \& ii): * patients with ctcl who have progressive, persistent or recurrent disease subsequent to at least one prior therapy * eastern cooperative oncology group (ecog) performance status must be 0-2 * patients have adequate bone marrow, liver function and renal function exclusion criteria (parts i \& ii): * patients had prior therapy within 3 weeks before registration, or have not recovered from toxicities of prior therapy * patients have uncontrolled intercurrent illness * pregnant or women have a will to be pregnant and lactating woman
urinary biomarkers characteristic to interstitial cystitis

Conditions: Interstitial Cystitis

Summary: this is a retrospective study of urine samples stored in the beaumont biobank for future research. the urine samples will be drawn from the urine back with patients previously diagnosed with severe interstitial cystitis (ic), mild ic and no ic. interstitial cystitis (ic) also known as painful bladder syndrome (pbs) is a chronic inflammatory disease. it has an unknown etiology, symptoms which present to varying degrees, as well as an uncertain natural history. diagnosis of ic is based on symptoms after excluding more common and dangerous pathologies.

extensive research has been done to understand the multifactorial etiology as well as to help diagnose ic. infectious, autoimmune and anatomic causes have been looked at with few usable results. inflammatory cells and markers have been more productive. recently we have shown in the rat model, that chemically induced inflammation, yields temporal increases in measurable cytokines and chemokines in the urine. moreover, this was done by multiplex analysis, using a multiple antigen bead assay (luminex). cytokines and chemokines, part of an organisms proteome, allow for looking at the function of a cell or organ at the time of the collection united states: institutional review board. urine is obtained non-invasively and yields significant information about urinary tract organs. the ability to find a biomarker or pattern of biomarker in the urine, diagnostic to a disease, offers significant advantages over serum or tissue diagnosis. we hope to identify patterns of inflammatory markers using proteomic analysis using the previously mentioned multiple antigen cassettes (luminex) as well as identify possible new biomarkers using a protein chip seldi--tof (surface enhanced laser desorption ionisation-time of flight) mass spectrometer. the detection of patterns or new biomarkers has promise to help with diagnosis, treatment, and ultimately revealing the etiology and course of ic.

Eligibility criteria:
inclusion criteria: * patients who have previously been contacted and consented to place a sample within the biobank. we will select five representative patients from the severe ic diagnosis, mild ic diagnosis, and no ic diagnosis, and we will match these patients as best as possible within the limited biobank samples. exclusion criteria: * none

Keywords: interstitial cystitis painful bladder syndrome
real-time (trus) guidance in endoscopic treatment of bph

Conditions: BPH (Benign Prostatic Hyperplasia)

Summary: the study aims to evaluate the role of trus in improving the efficacy and safety of endoscopic enucleation of prostate and turp.

standard turp is an established procedure for managing bph but has limitations, including the risk of incomplete adenoma removal and complications such as bleeding. research on transurethral enucleation techniques has demonstrated potential for improved outcomes, especially in larger prostates. however, challenges persist in achieving precise resection boundaries and minimizing intraoperative risks. trus, widely utilized for prostate biopsy and volume assessment, has recently gained attention for its intraoperative applications. studies show that real-time trus provides accurate imaging of prostate anatomy and resection planes, helping surgeons better differentiate adenomatous tissue from surrounding structures. this enhances surgical precision, reduces intraoperative bleeding, and minimizes residual tissue, leading to better outcomes in procedures like turp and enucleation. current turp and enucleation approaches depend heavily on endoscopic visual guidance, which, despite significant advancements, can lead to residual tissue, excessive bleeding, and prolonged recovery. while enucleation techniques have addressed some of these challenges, they remain less accessible due to high costs and steep learning curves, making them unsuitable for all healthcare settings. integrating trus into turp or enucleation offers the potential to address these limitations by enhancing tissue differentiation and guiding precise resection. this study aims to evaluate the efficacy of trus in reducing complications, achieving complete tissue removal, and improving patient recovery outcomes, potentially paving the way for its routine adoption in bph surgery.

Eligibility criteria:
inclusion criteria: * male patients aged 50-80 years * diagnosed with benign prostatic hyperplasia (bph) and scheduled for turp or prostatic adenoma enucleation. * the patients have clear indication for endoscopic surgery (according to the guidelines). * clinically fit patients for surgery. * signed an informed consent. exclusion criteria: * • prostate cancer * previous urethral or prostate surgery * neurogenic bladder * urethral stricture
lovastatin in reducing side effects after radiation therapy in women with breast cancer

Conditions: Breast Cancer; Radiation Toxicity

Summary: rationale: drugs, such as lovastatin, may protect normal cells from the side effects of radiation therapy. purpose: this phase ii trial is studying how well lovastatin works in reducing side effects after radiation therapy in women with breast cancer.

objectives: * to determine the incidence of good/excellent cosmetic outcome, as defined by the harvard scale, after radiotherapy in women treated with lovastatin, as compared to historical controls. outline: patients undergo standard external beam whole-breast irradiation and/or accelerated partial breast irradiation. patients receive oral lovastatin once daily beginning on the first day of radiotherapy and continuing for 12 months in the absence of disease progression or unacceptable toxicity. patients complete a questionnaire, the breast cancer treatment outcome scale, at baseline and then at 6 months, 12 months, and 3 years after completion of radiotherapy to assess cosmetic and functional outcomes. after completion of radiotherapy, patients are followed periodically for up to 5 years.

Eligibility criteria:
disease characteristics: * diagnosis of invasive or in situ epithelial cancer of the breast * stage 0, i, or ii (tis, t1, or t2) disease * unifocal disease (single focus that can be encompassed by breast-conserving surgery) * has undergone prior surgical resection of the primary lesion (lumpectomy) and axillary nodal evaluation (if invasive disease is present) * negative surgical margins (≥ 1 mm) * planning to undergo radiotherapy with either standard external beam radiotherapy or accelerated partial breast irradiation (interstitial or balloon brachytherapy) * no paget disease of the nipple * no evidence of distant metastases * hormone receptor status not specified patient characteristics: * menopausal status not specified * karnofsky performance status 70-100% * transaminases \< 3 times upper limit of normal (uln) * creatine kinase \< 5 times uln * creatinine clearance ≥ 30 ml/min * negative pregnancy test * no active liver or muscle disease * no history of collagen vascular disease (e.g., systemic lupus erythematosus, scleroderma, or dermatomyositis) * history of prior malignancy allowed provided life expectancy is ≥ 4 years * no major medical or psychiatric illness that, in the investigator's opinion, would prevent completion of study treatment or interfere with follow-up * no contraindication to an hmg-coa-reductase inhibitor prior concurrent therapy: * see disease characteristics * no prior radiotherapy to the breast, lung, or mediastinum * prior radiotherapy to the contralateral breast allowed * no chemotherapy for ≥ 2 weeks prior to, during, and for ≥ 2 weeks after completion of radiotherapy * no concurrent cytochrome p450 3a4 inhibitors * concurrent hmg-coa-reductase inhibitor allowed provided patient is able to switch to 20 mg of lovastatin per day * concurrent tamoxifen or an aromatase inhibitor allowed

Keywords: radiation toxicity stage ia breast cancer stage ib breast cancer stage ii breast cancer breast cancer in situ
preoperative herceptin/navelbine versus taxotere/carboplatin/herceptin in her-2 positive breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to find out what effects the preoperative combination therapies of herceptin/navelbine or herceptin/taxotere/carboplatin will have on patients with early stage her-2 positive breast cancer.

before starting treatment, a clip will be placed via catheter into the tumor bed, so the surgeon can locate the site of the tumor. during clip placement, tissue biopsy will be taken of the tumor. one to two weeks after the first dose of herceptin another biopsy will be performed. patients will be placed into one of 2 arms. * arm 1 receives 12 weeks of herceptin and navelbine. arm 2 receives 4 cycles of taxotere/carboplatin/herceptin. * arm 2 participants will also receive neulasta (growth factor support) on day 2 of each cycle. phase a of arm 1 is one dose of herceptin followed by an mri of the affected breast and a second biopsy 1-2 weeks following this dose. phase b of arm 1 begins on week 3 and ends on week 14 and involves weekly injections of herceptin and navelbine. surgery will take place a minimum of 3 weeks after the patients last dose of herceptin and navelbine. phase a of arm 2 is one dose of herceptin followed by an mri of the affected breast and second biopsy 1-2 weeks following this dose. phase b of arm 2 begins on week 3 and ends on week 14 and involves herceptin weekly, taxotere and carboplatin every 3 weeks. surgery will take place a minimum of 3 weeks after the patients last dose of herceptin, taxotere and carboplatin. blood tests will be performed every 3 weeks during pre-operative treatment and every 6 months after surgery.

Eligibility criteria:
inclusion criteria: * patients with stage ii or iii breast cancer * her-2 positive tumors * older than 18 years of age * eastern cooperative oncology group (ecog) performance status of greater or equal to 1. * anc \> 1,500/mm3 * hemoglobin \> 9gm/dl * platelets \> 100,000mm3 * creatinine \< 2mg/dl * glucose \< 200mg/dl * bilirubin \< 1.5 x uln exclusion criteria: * previous treatment with herceptin, taxanes, doxorubicin or other anthracycline-type therapy, navelbine, or platinum-based therapy. * pregnant or breast-feeding women * serious illness, or medical or psychiatric condition * uncontrolled infections * active or severe cardiovascular or pulmonary disease * patients with left ventricular ejection fraction \< 50% * peripheral neuropathy of any etiology that exceeds grade 1 * prior history of malignancy * uncontrolled diabetes

Keywords: her-2 positive breast cancer herceptin navelbine taxotere carboplatin early stage breast cancer
mobile chat messaging for alcohol reduction in patients with chronic liver diseases

Conditions: Chronic Liver Disease

Summary: the goal of this pilot randomized controlled trial is to evaluate the trial feasibility and acceptability of mobile chat messaging for reducing alcohol use among patients with chronic liver diseases. specific objectives include: 1. to assess whether the eligibility criteria were too restrictive by estimating the eligibility rate 2. to assess how many eligible cld patients accepted the invitation to participate in the trial 3. to assess the participant retention rate through 6 months after treatment initiation 4. to assess the intervention acceptability in terms of participants' engagement with and rating of the chat messaging intervention. 5. to assess the safety of the intervention 6. to estimate the intervention effect on alcohol use outcomes and liver functions 7. to synthesise data to inform the sample size calculation in the future definitive trial 8. to explore the participants' perception and experiences in the chat-based intervention


Eligibility criteria:
inclusion criteria: 1. age ≥18 years 2. diagnosed with chronic liver disease 3. alcohol use disorders identification test score ≥8 4. own a smartphone with a mobile instant messaging app installed 5. able to read and communicate in chinese exclusion criteria: 1. having a psychiatric or psychological disease or on psychotropic drugs 2. participating in other alcohol reduction or abstinence programmes 3. require emergency or in-patient treatment after consultation

Keywords: drinking cirrhosis hepatitis sbirt whatsapp chinese mhealth abi
effect of exercise on smokers

Conditions: Smokers

Summary: when we look at the literature, although 202 results are found when "high intensity training" and "aerobic" is written in the pubmed database, 27 to 86 results are found when "high intensity training" and "cognitive" and "high intensity training" and "respiratory" are written and searched. 5 results are found when "high intensity training" and "smoking" is searched, but there is no study investigating cognitive and respiratory functions, and no results are found when "high intensity training" and "smoker" is searched. as far as is known, there is no study investigating the acute effect of high intensity aerobic exercise on respiratory functions and cognitive status in special education personnel who smoke. we aim to contribute to the literature with this original aspect of our study.

primary objective: the primary objective of the study is to investigate the acute effects of high-intensity aerobic exercise on respiratory functions in special education personnel who smoke. secondary objective: the secondary objective of the study is to investigate the acute effects of high-intensity aerobic exercise on cognitive status in special education personnel who smoke. study questions * is there an acute effect of high-intensity aerobic exercise on respiratory functions in special education personnel who smoke? * is there an acute effect of high-intensity aerobic exercise on cognitive status in special education personnel who smoke? study hypotheses: h0: there is no acute effect of high-intensity aerobic exercise on respiratory functions in special education personnel who smoke. h1: there is an acute effect of high-intensity aerobic exercise on respiratory functions in special education personnel who smoke. h2: there is no acute effect of high-intensity aerobic exercise on cognitive status in special education personnel who smoke. h3: high-intensity aerobic exercise has an acute effect on cognitive status in special education personnel who smoke. h4: high-intensity aerobic exercise has a greater acute effect on respiratory function and cognitive status in special education personnel who smoke than low-intensity training. h5: high-intensity aerobic exercise has a less acute effect on respiratory function and cognitive status in special education personnel who smoke than low-intensity training.

Eligibility criteria:
inclusion criteria: * volunteering to participate in the study * participating in the fageström nicotine dependence questionnaire * no comorbidities * no comorbid diseases related to the orthopedic, neurological, cardiopulmonary system * participants who have not participated in another clinical trial in the last month exclusion criteria: * participants who have had orthopedic and cardiopulmonary surgery in the last year * those with cardiac or pulmonary system disease * having sensory loss * participants with leg length inequality

Keywords: smoker aerobic exercise
evaluating the efficacy and safety of hcp1105 in combined hyperlipidemic patients with high risk for chd

Conditions: Hyperlipidemias

Summary: to investigate the efficacy and safety after administration of hcp1105 in hyperlipidemic patients with high risk for chd.

an efficacy and safety study of hcp1105 capsule in combined hyperlipidemic patients with high risk for coronary heart disease(chd): a randomized,double-blind, multicenter, phase 3 study.

Eligibility criteria:
inclusion criteria: * age 19≤ * subjects who have ability to comprehend the objectives, contents of study and property of study drug before participating in trial and have willingness to sign of informed consent in writing exclusion criteria: * history of clinically significant hypersensitivity reaction with hmg-coa reductase inhibitor and omega-3 * subject who has active liver disease and severe liver failure(continuous elevation of ast,alt level with unspecified cause or ast, alt level exceeds more than three times of maximum upper range.)
screening intracranial aneurysms with magnetic resonance angiography (mra) in china

Conditions: Intracranial Aneurysm

Summary: the chinese cerebral aneurysms survey is a continuing prospective study among middle-aged and older individuals (35 - 75 years) that aims to determine the prevalence of cerebral intracranial aneurysms in the general population with mra at 3.0 tesla (t).

cerebral intracranial aneurysms are common. in angiographic and autopsy studies, estimates for prevalence vary between 0.2 and 9.9 percent. the methods used to detect the aneurysms markedly influenced the proportion of aneurysms. retrospective autopsy studies probably give an underestimation and prospective angiography studies an overestimation of the actual prevalence. accurate data on the prevalence of intracranial aneurysms are essential in evaluating the results of screening programs for aneurysms in general population. during the past decade, mra, as a preferred accuracy modality for noninvasive intracranial vascular imaging at most centers, is playing an increasing role in the evaluation of patients suspected of having intracranial aneurysms. in recurrent study, we have tested that mra at 3t has excellent sensitivity, accuracy, and correlation with dsa and is comparable to catheter cerebral angiography for the evaluation of patients with intracranial aneurysms (stroke, in press). therefore, we examined trends in intracranial aneurysm prevalence with the use of mra at 3.0t to determine the true prevalence of cerebral intracranial aneurysms in the general middle-aged or elder population.

Eligibility criteria:
inclusion criteria: * native inhabitants lived in a defined area sites in china * aged 35-75 years exclusion criteria: * less than 35 years old or more than 75 years old * incompetent patient who cannot give consent for routine mr angiography and his/her surrogate decision maker is not available * any patients with a contraindication to having a standard mri examination, such as phase maker, orbital metallic foreign body, etc.

Keywords: magnetic resonance angiography intracranial aneurysm cerebral aneurysm unruptured aneurysm epidemiology magnetic resonance imaging